Antimycotic Activity of Essential Oil of Origanum heracleoticum L. from Bulgaria Against Clinical Isolates of Candida spp.
Source abstract
Abstract
The component composition of Bulgarian essential oil from Origanum heracleoticum L. was determined by gas chromatography and mass spectrometry analysis. Fifty-three different compounds were identified in the essential oil, with carvacrol (70.31–70.52%) and p-cymene (10.86–11.03%) determined to be the main components. The antimicrobial activity of the essential oil was determined against 138 clinical isolates of four species of Candida spp., and it was found to exhibit high antimycotic activity (minimal inhibitory concentration (MIC) between 64 μg mL−1 and 128 μg mL−1) against both fluconazole-sensitive and fluconazole-resistant strains. It was found that Bulgarian essential oil from O. heracleoticum L. disrupts the normal permeability of the cell membrane and inhibits some of the main virulence factors of medically important fungi in the genus Candida by preventing germination, transition to the filamentous stage of growth and the production of hydrolytic enzymes.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Essential Oils and Antimicrobial Activity · Antifungal resistance and susceptibility · Sesquiterpenes and Asteraceae Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry and Microbiology, Faculty of Biology, “Paisii Hilendarski” University of Plovdiv, 4000 Plovdiv, Bulgaria
Department of Epidemiology and Disaster Medicine, Faculty of Public Health, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria
Scientific and Research Laboratory, Centre for Research Projects and Technological Transfer, University of Food Technologies, 4000 Plovdiv, Bulgaria
Agricultural Academy, Sofia, Institute of Food Preservation and Quality-Plovdiv, 154 Vasil Aprilov Blvd., 4000 Plovdiv, Bulgaria
References (88)
Show source-provided references
1. The WHO fungal priority pathogens list: A crucial reappraisal to review the prioritisation10.1016/S2666-5247(24)00042-9 ↗
2. WHO (2025, October 04). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. Available online: https://www.who.int/publications/i/item/9789240060241.
3. CDC (2025, October 04). Data and Statistics on Candidemia, Available online: https://www.cdc.gov/candidiasis/data-research/facts-stats/index.html.
4. Population-Based Active Surveillance for Culture-Confirmed Candidemia—10 Sites, United States, 2017–202110.15585/mmwr.ss7404a1 ↗
5. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States10.1128/AAC.47.10.3149-3154.2003 ↗
6. Update on antifungal resistance and its clinical impact10.1007/s12281-013-0143-0 ↗
7. Epidemiology of invasive candidiasis
8. Kantardzhiev, T. (2012). Etiological Diagnosis and Etiotropic Therapy of Mycoses, National Centre for Infectious and Parasitic Diseases. (In Bulgarian).
9. Hitkova, H.Y., Georgieva, D.S., Hristova, P.M., Marinova-Bulgaranova, T.V., Borisov, B.K., and Popov, V.G. (2020). Antifungal susceptibility of non-albicans Candida species in a tertiary care hospital, Bulgaria. Jundishapur J. Microbiol., 13.10.5812/jjm.101767 ↗
10. Species distribution and antifungal susceptibility of vaginal Candida isolates10.58395/2enj2697 ↗
11. Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans10.1128/EC.00445-07 ↗
12. Yang, Y.-L., Cheng, M.-F., Chang, Y.-W., Young, T.-G., Chi, H., Lee, S.C., Cheung, B.M.-H., Tseng, F.-C., Chen, T.-C., and Ho, Y.-H. (2008). Host factors do not influence the colonization or infection by fluconazole-resistant Candida species in hospitalized patients. J. Negat. Results Biomed., 7.10.1186/1477-5751-7-12 ↗
13. Virulence factors and antifungal sensitivity pattern of Candida spp. isolated from HIV and TB patients10.1007/s12088-011-0177-3 ↗
14. Pathogenesis and virulence of Candida albicans10.1080/21505594.2021.2019950 ↗
15. Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., and Škrlec, I. (2021). Candida albicans—The virulence factors and clinical manifestations. J. Fungi, 7.10.3390/jof7020079 ↗
16. Candidalysin biology and activation of host cells10.1128/mbio.00603-24 ↗
17. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance10.1128/CMR.12.4.501 ↗
18. Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils10.1002/med.20050 ↗
19. Epidemiologic features of vulvovaginal candidiasis among reproductive-age women in India10.1155/2012/859071 ↗
20. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies10.1093/jac/46.3.479 ↗
21. In vitro susceptibility of Candida spp. isolated from oral cavity of HIV/AIDS patients to itraconazole, clotrimazole and ketoconazole
22. Mulu, A., Kassu, A., Anagaw, B., Moges, B., Gelaw, A., Alemayehu, M., Belyhun, Y., Biadglegne, F., Hurissa, Z., and Moges, F. (2013). Frequent detection of ‘azole’ resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect. Dis., 13.10.1186/1471-2334-13-82 ↗
23. Antibacterial and antifungal properties of essential oils10.2174/0929867033457719 ↗
24. Anti-Candida albicans activity, cytotoxicity and interaction with antifungal drugs of essential oils and extracts from aromatic and medicinal plants10.1016/S0123-9392(11)70080-7 ↗
25. Assessment of antifungal activity of herbal and conventional toothpastes against clinical isolates of Candida albicans10.1016/S2221-1691(12)60059-8 ↗
26. Susceptibilities of Candida albicans mouth isolates to antifungal agents, essential oils and mouth rinses10.1007/s11046-012-9520-4 ↗
27. Antifungal activity of Thymus vulgaris L. essential oil and its constituent phytochemicals against Rhizopus oryzae: Interaction with ergosterol10.3390/molecules171214418 ↗
28. Antimycotic activity of Myrtus communis L. towards Candida spp. from isolates10.3855/jidc.2799 ↗
29. Antifungal effect of some plant oils against some oral clinical isolates of Candida albicans in Lebanese community
30. Are plant extracts a potential therapeutic approach for genital infections?10.2174/09298673113209990007 ↗
31. Argemone mexicana L.: Plant profile, phytochemistry and pharmacology—A review
32. Allizond, V., Cavallo, L., Roana, J., Mandras, N., Cuffini, A.M., Tullio, V., and Banche, G. (2023). In vitro antifungal activity of selected essential oils against Aspergillus spp.. Molecules., 28.10.3390/molecules28217259 ↗
33. A new potential resource in the fight against Candida auris: Essential oils10.1128/spectrum.04385-22 ↗
34. Fernandes, L., Furtado, G.H.C., Gimenes, F., Caetano, M., Magário, M.K.W., and Consolaro, M.E.L. (2023). Effect of vapor-phase oregano essential oil on biofilms of antifungal-resistant vaginal isolates of Candida species. Antibiotics, 12.
35. Balef, S.S.H., Hosseini, S.S., Asgari, N., Sohrabi, A., and Mortazavi, N. (2024). The inhibitory effects of carvacrol, nystatin, and their combination on oral candidiasis isolates. BMC Res. Notes, 17.10.1186/s13104-024-06767-y ↗
36. Kowalczyk, A. (2024). Essential Oils against Candida auris—A Promising Approach for Antifungal Activity. Antibiotics, 13.10.3390/antibiotics13060568 ↗
37. Yuan, X., Liu, Y., Li, Y., and Zhang, Y. (2024). Antifungal activity of essential oils and their potential against stationary-phase Candida albicans. Sci. Rep., 14.
38. Potente, G., Bonvichini, F., Gentilomi, G.A., and Antognoni, F. (2020). Anti-Candida activity of essential oils from Lamiaceae: Focus on Mediterranean taxa. Plants, 9.10.3390/antibiotics9070395 ↗
39. Karpiński, T.M. (2023). Anti-Candida and antibiofilm activity of selected Lamiaceae essential oils. Front. Biosci., 28.10.31083/j.fbl2802028 ↗
40. Hou, G.W., and Huang, T. (2024). Essential oils as promising treatments for treating Candida albicans infections: Research progress, mechanisms, and clinical applications. Front. Pharmacol., 15.10.3389/fphar.2024.1400105 ↗
41. Touati, A., Mairi, A., Ibrahim, N.A., and Idres, T. (2025). Essential oils for biofilm control: Mechanisms, synergies, and translational challenges. Antibiotics, 14.10.3390/antibiotics14050503 ↗
42. Mechanistic insight into the membrane-disrupting properties of thymol in Candida species10.1016/j.microb.2024.100045 ↗
43. Baycheva, S. (2017, January 19–20). Chemical composition of oregano essential oil (Origanum heracleoticum L.). Proceedings of the International Conference on Technics, Technologies and Education (ICTTE), Yambol, Bulgaria. (In Bulgarian).
44. Chemical composition of Bulgarian white oregano (Origanum heracleoticum L.) essential oils10.1088/1757-899X/1031/1/012107 ↗
45. Antimicrobial activity of Bulgarian white oregano essential oils and ethanol extracts10.1063/5.0173018 ↗
46. Application of essential oils and ethanol extracts of Bulgarian white oregano as additives in cooked-smoked sausages10.1063/5.0173017 ↗
47. Oregano essential oil inhibits Candida spp. biofilms10.1515/znc-2021-0002 ↗
48. Cid-Chevecich, C., Müller-Sepúlveda, A., Jara, J.A., López-Muñoz, R., Santander, R., Budini, M., Escobar, A., Quijada, R., Criollo, A., and Díaz-Dosque, M. (2022). Origanum vulgare L. essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. BMC Complement. Med. Ther., 22.10.1186/s12906-022-03518-z ↗
49. Niu, C., Wang, C., Yang, Y., Chen, R., Zhang, J., Chen, H., Zhuge, Y., Li, J., Cheng, J., and Xu, K. (2020). Carvacrol induces Candida albicans apoptosis associated with Ca2+/calcineurin pathway. Front. Cell. Infect. Microbiol., 10.10.3389/fcimb.2020.00192 ↗
50. Mączka, W., Gornowicz-Porowska, J., and Nowak, G. (2023). Carvacrol—A natural phenolic compound with antimicrobial and antibiofilm activity. Molecules, 28.10.3390/antibiotics12050824 ↗
51. (2001). Essential Oils—Determination of Relative Density at 20 °C (Standard No. BDS ISO 279:2001).
52. (1999). Essential Oils—Determination of Refractive Index—Comparative Method (Standard No. BDS ISO 280:1999).
53. (2001). Essential Oils—Determination of Optical Rotation (Standard No. BDS ISO 592:2001).
54. (2002). Essential Oils—Determination of Acid Number (Standard No. BDS ISO 1242:2002).
55. (2003). Essential Oils—Determination of Ester Number (Standard No. BDS ISO 709:2003).
56. Adams, R.P. (2007). Identification of Essential Oil Components by Gas Chromatography/Mass Spectrometry, Allured Publishing. [4th ed.].
57. Jennings, W., and Shibamoto, T. (1980). Qualitative Analysis of Flavor and Fragrance Volatiles by Glass Capillary Gas Chromatography, Academic Press.
58. Kondjoyan, N., and Berdagué, J.-L. (1996). A Compilation of Relative Retention Indices for the Analysis of Aromatic Compounds, Laboratoire d’Etude des Arômes.
59. Joulain, D., and König, W.A. (1998). The Atlas of Spectral Data of Sesquiterpene Hydrocarbons, E.B.-Verlag.
60. Clinical and Laboratory Standards Institute (CLSI) (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, CLSI. [4th ed.]. CLSI standard M27.
61. Activities of essential oils in the inhibition of Candida albicans and Candida dubliniensis germ tube formation10.1016/j.mycmed.2010.06.003 ↗
62. Evaluation of a GC-MS method for the analysis of oregano essential oil composition
63. Field studies of nitrogen application on Greek oregano (Origanum vulgare ssp. hirtum (Link) Letswaart) essential oil during two cultivation seasons10.1016/j.indcrop.2013.01.021 ↗
64. Potential health benefits of Origanum heracleoticum essential oil: Phytochemical and biological variability among different Calabrian populations
65. Napoli, E., Giovino, A., Carrubba, A., How Yuen Siong, V., Rinoldo, C., Nina, O., and Ruberto, G. (2020). Variations of essential-oil constituents in oregano (Origanum vulgare subsp. viridulum (= O. heracleoticum)) over cultivation cycles. Plants, 9.10.3390/plants9091174 ↗
66. Amato, G., Caputo, L., Francolino, R., Martino, M., De Feo, V., and De Martino, L. (2023). Origanum heracleoticum essential oils: Chemical composition, phytotoxic and α-amylase inhibitory activities. Plants, 12.10.3390/plants12040866 ↗
67. Impact of both the season of collection and drying on volatile constituents of Origanum vulgare L. ssp. hirtum grown wild in Croatia
68. Antimicrobial effect of selected plant essential oils on the growth of a Pseudomonas putida strain isolated from meat10.1016/j.meatsci.2005.11.019 ↗
69. LC-MS method for the simultaneous quantitation of the anti-inflammatory constituents in oregano (Origanum species)10.1021/jf100636h ↗
70. Behaviour of Listeria monocytogenes and autochthonous flora on meat stored under aerobic, vacuum and modified atmosphere packaging conditions with or without the presence of oregano essential oil at 5 °C10.1046/j.1365-2672.2000.01170.x ↗
71. Inhibitory effects of selected essential oils on the growth of four pathogenic bacteria: Escherichia coli O157:H7, Salmonella Typhimurium, Staphylococcus aureus and Listeria monocytogenes10.1016/j.foodcont.2005.11.009 ↗
72. Evaluation of oregano essential oil (Origanum heracleoticum L.) on growth, antioxidant effect and resistance against Aeromonas hydrophila in channel catfish (Ictalurus punctatus)10.1016/j.aquaculture.2009.04.025 ↗
73. Effect of Origanum heracleoticum L. Essential oil on food-borne Penicillium aurantiogriseum and Penicillium chrysogenum isolates
74. Antifungal activities of Origanum vulgare subsp. hirtum, Mentha spicata, Lavandula angustifolia and Salvia fruticosa essential oils against human pathogenic fungi10.1021/jf9708296 ↗
75. Della Pepa, T., Elshafie, H.S., Capasso, R., De Feo, V., Camele, I., Nazzaro, F., Scognamiglio, M.R., and Caputo, L. (2019). Antimicrobial and phytotoxic activity of Origanum heracleoticum and O. majorana essential oils growing in Cilento (Southern Italy). Molecules, 24.10.3390/molecules24142576 ↗
76. In vitro activity of terpenes against Candida biofilms10.1016/j.ijantimicag.2008.01.028 ↗
77. Marcos-Arias, C., Eraso, E., Madariaga, L., and Quindós, G. (2011). In vitro activities of natural products against oral Candida isolates from denture wearers. BMC Complement. Altern. Med., 11.10.1186/1472-6882-11-119 ↗
78. Killing Kinetics of carvacrol against fluconazole-susceptible and -resistant isolates of Candida tropicalis10.61186/mlj.17.1.27 ↗
79. The efficacy and safety of sertaconazole cream (2%) in diaper dermatitis candidiasis10.1007/s11046-013-9642-3 ↗
80. the mode of antimicrobial action of the essential oil of Melaleuca alternifolia (Tea Tree Oil)10.1046/j.1365-2672.2000.00943.x ↗
81. The effect of osmotic pressure on the membrane fluidity of Saccharomyces cerevisiae at different physiological temperatures10.1007/s002530000583 ↗
82. Antifungal activity of local anesthetics against Candida Species10.1155/S1064744900000168 ↗
83. Acuña, E., Contador, R., Pereira, M., Aguilera, J., Berríos, J., and Fuentes-López, M. (2023). Carvacrol-induced vacuole dysfunction and morphological consequences in nakaseomyces glabratus and Candida albicans. Microorganisms, 11.10.3390/microorganisms11122915 ↗
84. Preda, M., Bumbac, R., Dumitru, I., Bostan, M., and Ditu, L. (2024). Pathogenesis, prophylaxis, and treatment of Candida auris. Biomedicines, 12.10.3390/biomedicines12030561 ↗
85. Blocking the shikimate pathway amplifies the impact of carvacrol on Candida albicans by attenuating adhesion, hyphal and biofilm formation10.1128/spectrum.02754-24 ↗
86. Anti-Candida activity of essential oils10.2174/138955709789878150 ↗
87. secreted lipases of Candida albicans: Cloning, characterisation and expression analysis of a new gene family with at least ten members10.1007/s002030000218 ↗
88. Low-virulent oral Candida albicans strains isolated from smokers10.1016/j.archoralbio.2011.08.016 ↗